The global kidney cancer drugs market size is expected to be valued at USD 6.3 billion by 2022, as per a new report by Grand View Research, Inc., registering a CAGR of 5.4% during the forecast period. Market growth is largely driven by factors such as the availability of novel drugs and the presence of a strong pipeline. Growth can also be attributed to a rise in the incidence of renal cancer due to the growing geriatric population and changes in lifestyle such as increased smoking and intake of alcohol.
In 2012, kidney cancer was the 13th most prevalent cancer worldwide, accounting for approximately 2.0% of all adult malignancies. Kidney and renal pelvis cancer make up for 3.8% of all new cancer cases in U.S. Renal cell carcinoma account for over 90.0% of kidney carcinomas. Various forms of cancer treatment methods have been implemented among the currently approved drugs, including immune modulation therapy, cytokine therapy, mTOR inhibitor, and Vascular Endothelial Growth Factor (VEGF) inhibitor.
To request a sample copy or view summary of this report, click the link below:
Further key findings from the report suggest:
Increasing incidence of the disease and rising geriatric population globally are amongst major factors stimulating market growth
Novel agents have expanded market opportunities through a larger number of patients under treatment and better treatment prospects compared to traditional therapies. The notable clinical profile of immuno-oncology drugs is reflected in their rapid uptake and expansion of indications
The current treatment landscape in metastatic and advanced RCC will shift from TKI and mTOR inhibitors to specific immuno-oncology agents like immune checkpoint inhibitors (ICI), which have demonstrated positive results on PFS as monotherapy (Opdivo) or combination therapy (Opdivo+Yervoy)
The U.S. accounted for more than 35.0% of the market in 2016 due to the increasing incidence of renal cell carcinoma and the presence of key manufacturers in the country. On the other hand, surge in kidney cancer screening is a key driver in markets such as EU
Emerging markets in Asia Pacific and Middle East and Africa are fueled by increasing expenditure on healthcare, a large untapped patient population base due to rise in the elderly population, and improvement in diagnostic technologies
Some of the key players operating in this market are Pfizer, Novartis, Bayer, Bristol-Myers Squibb, Eisai, and Exelixis. Collaborations for development, broader product portfolios, and regional expansion in emerging markets are key strategic undertakings of these companies to increase market share.
Grand View Research has segmented the global kidney cancer drugs market based on therapeutic class, pharmacologic class, and country:
Kidney Cancer Drugs Therapeutic Class Outlook (USD Million, 2016 - 2022)
Kidney Cancer Drugs Pharmacologic Class Outlook (USD Million, 2016 - 2022)
Cytokine Immunotherapy (IL-2)
Kidney Cancer Drugs Country Outlook (USD Million, 2016 - 2022)
This report has a service guarantee. We stand by our report quality.
Your transaction & personal information is safe and secure.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
Avail customized purchase options to meet your research needs:
"The quality of research they have done for us has been excellent..."